340 related articles for article (PubMed ID: 20335174)
1. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells.
Yuan T; Wang Y; Zhao ZJ; Gu H
J Biol Chem; 2010 May; 285(20):14861-14870. PubMed ID: 20335174
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
3. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Asp N; Pust S; Sandvig K
Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling.
Du WW; Fang L; Li M; Yang X; Liang Y; Peng C; Qian W; O'Malley YQ; Askeland RW; Sugg SL; Qian J; Lin J; Jiang Z; Yee AJ; Sefton M; Deng Z; Shan SW; Wang CH; Yang BB
J Cell Sci; 2013 Mar; 126(Pt 6):1440-53. PubMed ID: 23418360
[TBL] [Abstract][Full Text] [Related]
5. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
[TBL] [Abstract][Full Text] [Related]
6. A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling.
Wong L; Deb TB; Thompson SA; Wells A; Johnson GR
J Biol Chem; 1999 Mar; 274(13):8900-9. PubMed ID: 10085134
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF.
Deb TB; Su L; Wong L; Bonvini E; Wells A; David M; Johnson GR
J Biol Chem; 2001 May; 276(18):15554-60. PubMed ID: 11279155
[TBL] [Abstract][Full Text] [Related]
9. Involvement of ErbB2 in the signaling pathway leading to cell cycle progression from a truncated epidermal growth factor receptor lacking the C-terminal autophosphorylation sites.
Sasaoka T; Langlois WJ; Bai F; Rose DW; Leitner JW; Decker SJ; Saltiel A; Gill GN; Kobayashi M; Draznin B; Olefsky JM
J Biol Chem; 1996 Apr; 271(14):8338-44. PubMed ID: 8626530
[TBL] [Abstract][Full Text] [Related]
10. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
Zhan L; Xiang B; Muthuswamy SK
Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
[TBL] [Abstract][Full Text] [Related]
11. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
Badache A; Hynes NE
Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
[TBL] [Abstract][Full Text] [Related]
13. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases.
Olayioye MA; Beuvink I; Horsch K; Daly JM; Hynes NE
J Biol Chem; 1999 Jun; 274(24):17209-18. PubMed ID: 10358079
[TBL] [Abstract][Full Text] [Related]
14. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
Yoon SO; Shin S; Lipscomb EA
Cancer Res; 2006 Mar; 66(5):2732-9. PubMed ID: 16510594
[TBL] [Abstract][Full Text] [Related]
15. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
[TBL] [Abstract][Full Text] [Related]
16. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
[TBL] [Abstract][Full Text] [Related]
17. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
18. Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.
Yu Y; Suryo Rahmanto Y; Shen YA; Ardighieri L; Davidson B; Gaillard S; Ayhan A; Shi X; Xuan J; Wang TL; Shih IM
EBioMedicine; 2019 Sep; 47():184-194. PubMed ID: 31492560
[TBL] [Abstract][Full Text] [Related]
19. CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells.
Wobus M; Rangwala R; Sheyn I; Hennigan R; Coila B; Lower EE; Yassin RS; Sherman LS
Appl Immunohistochem Mol Morphol; 2002 Mar; 10(1):34-9. PubMed ID: 11893033
[TBL] [Abstract][Full Text] [Related]
20. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.
Esparís-Ogando A; Díaz-Rodríguez E; Montero JC; Yuste L; Crespo P; Pandiella A
Mol Cell Biol; 2002 Jan; 22(1):270-85. PubMed ID: 11739740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]